Brief: MoonLake Immunotherapeutics Signs Development And Manufacturing Agreement With Vetter Pharma International GmbH

MoonLake Immunotherapeutics

26/07/2022 13:24

July 26 (Reuters) - MoonLake Immunotherapeutics  MLTX.O :
    * MOONLAKE IMMUNOTHERAPEUTICS SIGNS DEVELOPMENT AND
MANUFACTURING
AGREEMENT WITH VETTER PHARMA INTERNATIONAL GMBH
    * MOONLAKE IMMUNOTHERAPEUTICS - VETTER WILL BE RESPONSIBLE
FOR
ASEPTIC FILLING OF SYRINGES WITH SONELOKIMAB
    * MOONLAKE IMMUNOTHERAPEUTICS - VETTER WILL BE RESPONSIBLE
FOR
SUBSEQUENT ASSEMBLY INTO AN AUTOINJECTOR COMBINATION DEVICE AND
PACKAGING
    * MOONLAKE - DEVELOPMENT STUDIES ASSOCIATED WITH
MANUFACTURING OF
SUB-CUTANEOUS SONELOKIMAB FOR TRIALS, COMMERCIAL VOLUMES HAVE
CONCLUDED
    * MOONLAKE IMMUNOTHERAPEUTICS - TECHNICAL ENGINEERING
BATCHES FOR
SONELOKIMAB STARTED IN Q2 2022
    * MOONLAKE IMMUNOTHERAPEUTICS - FIRST CLINICAL GOOD
MANUFACTURING
PRACTICE BATCHES ARE EXPECTED TO BE MANUFACTURED IN Q4 2022

Source text for Eikon:  ID:nGNXr38wz 
Further company coverage:  MLTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))